Physician profile
Jeffrey M Basile
NPI 1437393964
$5,142.51
in general payments reported to CMS, 2019-2025
30 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $148 · 2021: $70.74 · 2022: $225 · 2023: $768 · 2024: $1,167 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328 · Education: $22.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.23 |
| Education | $22.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,904.40 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Pfizer INC. | $346.11 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $344.11 | 2019-2023 | Stelara |
| Janssen Biotech, INC. | $328.29 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $245.66 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.67 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $227.38 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $165.29 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $161.55 | 2024-2025 | Vegzelma, Zymfentra |
| Sandoz INC. | $127.48 | 2023-2025 | Hyrimoz |
| Medical Device Business Services, INC. | $124.31 | 2019 | |
| Madrigal Pharmaceuticals | $117.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $107.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $103.95 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $84.50 | 2023-2025 | Ocaliva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $65.53 | 2022-2025 | |
| Celgene Corporation | $58.49 | 2024 | Zeposia |
| Lilly USA, LLC | $53.04 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $52.99 | 2025 | Iqirvo |
| Ambu INC. | $48.00 | 2021 | |
| Qol Medical, LLC | $47.53 | 2020-2023 | Sucraid |
| Daiichi Sankyo INC. | $41.22 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $31.11 | 2023-2024 | Dificid |
| Fresenius Kabi USA, LLC | $29.56 | 2023 | |
| Mirum Pharmaceuticals, INC. | $23.20 | 2025 | Livmarli |
| Braintree Laboratories, INC. | $19.03 | 2025 | Suflave, Sutab |
| Evoke Pharma, INC. | $14.43 | 2024 | |
| Boston Scientific Corporation | $13.45 | 2020 | |
| Shionogi INC | $12.70 | 2020 | |
| Allergan, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Basile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.